Cargando…

Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster

BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Huan, Male, Musa, Li, Yang, Wang, Ning, Zhao, Chenming, Jin, Shan, Hu, Juncheng, Chen, Zhiqiang, Ye, Zhangqun, Xu, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035412/
https://www.ncbi.nlm.nih.gov/pubmed/29980178
http://dx.doi.org/10.1186/s12882-018-0980-8
_version_ 1783338047206588416
author Yang, Huan
Male, Musa
Li, Yang
Wang, Ning
Zhao, Chenming
Jin, Shan
Hu, Juncheng
Chen, Zhiqiang
Ye, Zhangqun
Xu, Hua
author_facet Yang, Huan
Male, Musa
Li, Yang
Wang, Ning
Zhao, Chenming
Jin, Shan
Hu, Juncheng
Chen, Zhiqiang
Ye, Zhangqun
Xu, Hua
author_sort Yang, Huan
collection PubMed
description BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This research aims to evaluate the inhibition efficacy of Hydroxy-L-proline (HYP) analogs against calcium oxalate (CaOx) crystal formation in the Drosophila Melanogaster (D. Melanogaster) by comparing them with Pyridoxine (Vitamin B6). METHODS: Three stocks of Drosophila Melanogaster (W(118), CG3926 RNAi, and Act5C-GAL4/CyO) were utilized. Two stocks (CG3926 RNAi and Act5C-GAL4 /CyO) were crossed to generate the Act5C > dAGXT RNAi recombinant line (F(1) generation) of D. Melanogaster which was used to compare the efficacy of Hydroxy-L-proline (HYP) analogs inhibiting CaOx crystal formation with Vitamin B(6) as the traditional therapy for primary hyperoxaluria. RESULTS: Nephrolithiasis model was successfully constructed by downregulating the function of the dAGXT gene in D. Melanogaster (P-Value = 0.0045). Furthermore, the efficacy of Hydroxy-L-proline (HYP) analogs against CaOx crystal formation was demonstrated in vivo using D. Melanogaster model; the results showed that these L-Proline analogs were better in inhibiting stone formation at very low concentrations than Vitamin B(6) (IC(50) = 0.6 and 1.8% for standard and dietary salt growth medium respectively) compared to N-acetyl-L-Hydroxyproline (IC(50) = 0.1% for both standard and dietary salt growth medium) and Baclofen (IC(50) = 0.06 and 0.1% for standard and dietary salt growth medium respectively). Analysis of variance (ANOVA) also showed that Hydroxy-L-proline (HYP) analogs were better alternatives for CaOx inhibition at very low concentration especially when both genetics and environmental factors are intertwined (p < 0.0008) for the dietary salt growth medium and (P < 0.063) for standard growth medium. CONCLUSION: Addition of Hydroxy-L-Proline analogs to growth medium resulted in the reduction of CaOx crystals formation. These analogs show promise as potential inhibitors for oxalate reduction in Primary Hyperoxaluria.
format Online
Article
Text
id pubmed-6035412
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60354122018-07-09 Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster Yang, Huan Male, Musa Li, Yang Wang, Ning Zhao, Chenming Jin, Shan Hu, Juncheng Chen, Zhiqiang Ye, Zhangqun Xu, Hua BMC Nephrol Research Article BACKGROUND: Substrate reduction therapy with analogs reduces the accumulation of substrates by inhibiting the metabolic pathways involved in their biosynthesis, providing new treatment options for patients with primary hyperoxalurias (PHs) that often progress to end-stage renal disease (ESRD). This research aims to evaluate the inhibition efficacy of Hydroxy-L-proline (HYP) analogs against calcium oxalate (CaOx) crystal formation in the Drosophila Melanogaster (D. Melanogaster) by comparing them with Pyridoxine (Vitamin B6). METHODS: Three stocks of Drosophila Melanogaster (W(118), CG3926 RNAi, and Act5C-GAL4/CyO) were utilized. Two stocks (CG3926 RNAi and Act5C-GAL4 /CyO) were crossed to generate the Act5C > dAGXT RNAi recombinant line (F(1) generation) of D. Melanogaster which was used to compare the efficacy of Hydroxy-L-proline (HYP) analogs inhibiting CaOx crystal formation with Vitamin B(6) as the traditional therapy for primary hyperoxaluria. RESULTS: Nephrolithiasis model was successfully constructed by downregulating the function of the dAGXT gene in D. Melanogaster (P-Value = 0.0045). Furthermore, the efficacy of Hydroxy-L-proline (HYP) analogs against CaOx crystal formation was demonstrated in vivo using D. Melanogaster model; the results showed that these L-Proline analogs were better in inhibiting stone formation at very low concentrations than Vitamin B(6) (IC(50) = 0.6 and 1.8% for standard and dietary salt growth medium respectively) compared to N-acetyl-L-Hydroxyproline (IC(50) = 0.1% for both standard and dietary salt growth medium) and Baclofen (IC(50) = 0.06 and 0.1% for standard and dietary salt growth medium respectively). Analysis of variance (ANOVA) also showed that Hydroxy-L-proline (HYP) analogs were better alternatives for CaOx inhibition at very low concentration especially when both genetics and environmental factors are intertwined (p < 0.0008) for the dietary salt growth medium and (P < 0.063) for standard growth medium. CONCLUSION: Addition of Hydroxy-L-Proline analogs to growth medium resulted in the reduction of CaOx crystals formation. These analogs show promise as potential inhibitors for oxalate reduction in Primary Hyperoxaluria. BioMed Central 2018-07-06 /pmc/articles/PMC6035412/ /pubmed/29980178 http://dx.doi.org/10.1186/s12882-018-0980-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yang, Huan
Male, Musa
Li, Yang
Wang, Ning
Zhao, Chenming
Jin, Shan
Hu, Juncheng
Chen, Zhiqiang
Ye, Zhangqun
Xu, Hua
Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title_full Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title_fullStr Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title_full_unstemmed Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title_short Efficacy of Hydroxy-L-proline (HYP) analogs in the treatment of primary hyperoxaluria in Drosophila Melanogaster
title_sort efficacy of hydroxy-l-proline (hyp) analogs in the treatment of primary hyperoxaluria in drosophila melanogaster
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035412/
https://www.ncbi.nlm.nih.gov/pubmed/29980178
http://dx.doi.org/10.1186/s12882-018-0980-8
work_keys_str_mv AT yanghuan efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT malemusa efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT liyang efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT wangning efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT zhaochenming efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT jinshan efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT hujuncheng efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT chenzhiqiang efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT yezhangqun efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster
AT xuhua efficacyofhydroxylprolinehypanalogsinthetreatmentofprimaryhyperoxaluriaindrosophilamelanogaster